Triclabendazole is a benzimidazole-derived anthelmintic with selective activity against Fasciola species. It disrupts microtubule formation and energy metabolism in adult and immature flukes, making it the WHO-recommended first-line therapy for fascioliasis. Indicated for the treatment of fascioliasis (liver fluke infection) caused by Fasciola hepatica and Fasciola gigantica in patients aged 6 years and older, including both acute and chronic phases of infection.